Literature DB >> 21689092

Targeting PIM kinase activity significantly augments the efficacy of cytarabine.

Kevin R Kelly, Claudia M Espitia, Pietro Taverna, Gavin Choy, Swaminathan Padmanabhan, Steffan T Nawrocki, Francis J Giles, Jennifer S Carew.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21689092     DOI： 10.1111/j.1365-2141.2011.08792.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

1.  Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.

Authors:  Lisa S Chen; Ji-Yeon Yang; Han Liang; Jorge E Cortes; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2016-04-07

2.  Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.

Authors:  Fabiola Cervantes-Gomez; Lisa S Chen; Robert Z Orlowski; Varsha Gandhi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-08-27

3.  Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.

Authors:  Qingshan Yang; Lisa S Chen; Sattva S Neelapu; Roberto N Miranda; L Jeffrey Medeiros; Varsha Gandhi
Journal:  Blood       Date:  2012-09-06       Impact factor: 22.113

4.  Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.

Authors:  D Mahalingam; C M Espitia; E C Medina; J A Esquivel; K R Kelly; D Bearss; G Choy; P Taverna; J S Carew; F J Giles; S T Nawrocki
Journal:  Br J Cancer       Date:  2011-10-20       Impact factor: 7.640

Review 5.  Targeting the Pim kinases in multiple myeloma.

Authors:  N A Keane; M Reidy; A Natoni; M S Raab; M O'Dwyer
Journal:  Blood Cancer J       Date:  2015-07-17       Impact factor: 11.037

6.  A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.

Authors:  Jason M Foulks; Kent J Carpenter; Bai Luo; Yong Xu; Anna Senina; Rebecca Nix; Ashley Chan; Adrianne Clifford; Marcus Wilkes; David Vollmer; Benjamin Brenning; Shannon Merx; Shuping Lai; Michael V McCullar; Koc-Kan Ho; Daniel J Albertson; Lee T Call; Jared J Bearss; Sheryl Tripp; Ting Liu; Bret J Stephens; Alexis Mollard; Steven L Warner; David J Bearss; Steven B Kanner
Journal:  Neoplasia       Date:  2014-06-18       Impact factor: 5.715

7.  Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.

Authors:  Holly Koblish; Yun-Long Li; Niu Shin; Leslie Hall; Qian Wang; Kathy Wang; Maryanne Covington; Cindy Marando; Kevin Bowman; Jason Boer; Krista Burke; Richard Wynn; Alex Margulis; Gary W Reuther; Que T Lambert; Valerie Dostalik Roman; Ke Zhang; Hao Feng; Chu-Biao Xue; Sharon Diamond; Greg Hollis; Swamy Yeleswaram; Wenqing Yao; Reid Huber; Kris Vaddi; Peggy Scherle
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.